NPS Pharmaceuticals (NPSP) Target Raised to $47 at Leerink Swann

September 26, 2013 8:39 AM EDT Send to a Friend
Get Alerts NPSP Hot Sheet
Price: $26.93 -7.39%

Rating Summary:
    12 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade NPSP Now!
Join SI Premium – FREE
Leerink Swann maintained an Outperform rating on NPS Pharmaceuticals Inc. (NASDAQ: NPSP) and raised its price target to $47.00 (from $35.00). The change follow a Netpara survey that exceeded expectations.

Analyst Joseph P. Schwartz said, "Our findings from a recent MEDACorp survey of 30 endocrinologists in the US highlight a significant unmet medical need in chronic hypoparathyroidism (hypoPTH) and indicate that Natpara has the potential to become a staple of the standard-of-care. As stated in our recent Natpara Deep Dive, we are buyers of NPSP ahead of Natpara BLA filing in 4Q and additional details on management's view of the Natpara opportunity, which together, could broaden the Street's attention from the strong Gattex launch to Natpara's robust commercial potential in hypoPTH that we now project to be larger than Gattex at peak."

For an analyst ratings summary and ratings history on NPS Pharmaceuticals Inc. click here. For more ratings news on NPS Pharmaceuticals Inc. click here.

Shares of NPS Pharmaceuticals Inc. closed at $32.88 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Add Your Comment